Northstar Gets OK For Second Depression Study

Luke Timmerman10/14/08

Northstar Neuroscience, a Seattle medical device company, said today the FDA has given conditional approval to run a second study of its brain-stimulation device against depression. Northstar (NASDAQ: NSTR) said it plans to start enrolling the first of 24 patients in the study, called Prospect II, before the end of the year. Preliminary results should be available in the second half of 2009. The company switched its strategy this year to focus on depression after a pivotal study failed to restore arm movement for patients recovering from strokes.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.